Brief

"On November 29, 2024, the European Medicines Agency (EMA) issued an update regarding Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 25-28 November 2024. The PRAC concluded that currently available evidence does not support a link between doxycycline and suicidality risk, while new recommendations were agreed for Veoza to minimise the risk of liver injury through monitoring of liver function before and during treatment."

This content is restricted.

Highlights content goes here...

This content is restricted.

European Medicines Agency (EMA)

Quick Insight
RADA.AI
RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested

Form successfully submitted. One of our GRI rep will contact you shortly

Thanking You!

Enter your Email

Enter your registered username/email id.

Enter your Email

Enter your email id below to signup.
Individual Plan
$125 / month OR $1250 / year
Features
Best for: Researchers, Legal professionals, Academics
Enterprise Plan
Contact for Pricing
Features
Best for: Law Firms, Corporations, Government Bodies